Week of June 25, 2012: Bend Research, Catalent Enter into Oral Controlled-Release Technologies Pact; Quintiles Expands in China; and More - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week of June 25, 2012: Bend Research, Catalent Enter into Oral Controlled-Release Technologies Pact; Quintiles Expands in China; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

Adventrx and Patheon have entered into a manufacturing agreement under which Patheon will formulate, fill, and finish ANX-188 drug product for use in clinical trials, including the Phase III study of ANX-188 that AdventRX plans to initiate this year. Read More

Bend Research and Catalent Pharma Solutions have agreed to provide services for pharmaceutical companies seeking to develop and manufacture specialized multiparticulate oral controlled-release products. Under the agreement, the companies will provide an integrated approach designed to bring complex controlled-release products to market faster and more efficiently with optimal therapeutic and release profiles. Read More

Merck Serono and Compugen, a therapeutic product-discovery company, has established Neviah Genomics, a start-up company focused on the discovery and development of novel biomarkers for the prediction of drug-induced toxicity. Neviah Genomics will be operating out of the Merck Serono Israel Bioincubator. Merck Serono Ventures will provide the initial funding for Neviah Genomics. Compugen will use certain proprietary predictive discovery technologies and receive an equity ownership in the new company and a right to royalties from potential future sales. Read More

The CRO Quintiles has agreed to establish a regional headquarters in Shanghai, to significantly expand laboratory-testing capabilities in China. Under a joint venture agreement, Quintiles will engage Shanghai Clinical Research Center to provide laboratory-testing services to local customers. To provide the infrastructure essential for its growth strategy in China, Quintiles is investing $14 million to establish a new 4000-m2 (43,000 ft2) headquarters in Shanghai to serve China and nearby Asian countries. Read More

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here